Skip to main content
Premium Trial:

Request an Annual Quote

Timothy Ring and David Melcher

Becton Dickenson announced today that Timothy Ring and David Melcher have joined its board of directors. Ring has served as chairman and CEO of Bard since August 2003. He previously joined Bard in 1992 and has served as VP of human resources, group VP of Bard International, and in additional roles. Ring is also a director of Quest Diagnostics, a trustee for the New Jersey Health Foundation, and a board member for the Advanced Medical Technology Association. Melcher has been president and CEO of the Aerospace Industries Association since 2015. Prior to AIA, Melcher was president and CEO of Exelis, a spinoff of ITT Corporation. In addition to being a director for Bard, Melcher is also a member of the Federal Aviation Administration's NextGen Advisory Committe, providing advice on policy-level issues for US aviation modernization.  

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.